500 l from the supernatant, free of antibodies, that have precipitated, were mixed with 500 l of physiological serum and this sample was measured in the analyzer. carefully analyzing the results and ruling out possible interferences, as well as considering all kinds of pathologies, even if they are infrequent. Keywords: Insulin, C-peptide, Insulin autoantibody, Interference, Insulin autoimmune syndrome, Size exclusion chromatography 1.?Introduction Insulin is widely known as the principal anabolic hormone of human body. It is secreted by beta cells of the pancreatic islets to regulate mainly carbohydrate metabolism promoting the absorption of glucose from the blood to the liver, skeletal muscle and adipose tissue [1]. The conversation of genetic predisposition with environmental triggers could lead in some people to the production of insulin autoantibodies that can cause clinical alterations [2]. This condition is known as Ticlopidine HCl Insulin Autoimmune Syndrome (IAS), which is usually characterized by spontaneous crises of hypoglycemia and high levels of blood insulin and anti-insulin antibodies, in a context of no previous exogenous insulin exposure and no pathological alterations of the pancreatic islets [3]. In 1972, Yukimasa Hirata described the very first case of IAS in a 47-year-old Japanese man with severe spontaneous hypoglycemia, so this syndrome can be also known as Hirata’s disease [4]. IAS is especially common in East Asian countries (more than 90% of published cases up to 2009 occurred in the Japanese population), although the incidence among Caucasian people is usually increasing [2]. To some authors, this uneven geographical distribution is partially explained by the more prevalent immunogenic determinants of IAS (HLA-DR4, specifically DRB1*0406) in Asian populace [5]. Other triggers have been described as inductors of IAS: medication (specially drugs made up of sulfhydryl groups), viral infections and hematological and autoimmune diseases [6]. Due to their high linkage capacity, insulin autoantibodies (IAA) bind to secreted insulin forming large antigens-antibodies complexes and insulin becomes unable to exert its physiological effects, resulting in transient hyperglycemia. This hyperglycemia continues to stimulate the release of more insulin by pancreatic cells reaching a point where endogenous antibodies binding capacity is exceeded, so there will be free active insulin. In addition, after a while, the low affinity of IAA for insulin causes a spontaneously dissociation of the complexes and an excess of unbound insulin, which evokes hypoglycemia of varying severity [7]. This hypoglycemia is the responsible of the main clinical characteristics of IAS, which manifests with autonomic and neuroglycopenic symptoms that can be fatal for the patient if not treated in time [8]. Diagnosis of this condition requires careful analysis of clinical findings and laboratory test results. We present below the procedure followed by our clinical laboratory in a case of a patient with hypoglycemic attacks of unknown origin. 2.?Case presentation A 45-years-old Spanish man was referred to the Endocrinology Support complaining of dizziness and tremors that stop with the intake of carbohydrates. Capillary glucose concentrations measured Ticlopidine HCl during some of these crises were reported as being between 44 and 46 mg/dL. There was no history of diabetes mellitus, previous exposure to insulin or other reasons that could lower blood glucose such as alcoholism, liver disease and intake of drugs. The patient’s Body Mass Index (BMI) was 31 kg/m2. In 2005, he was diagnosed with immune thrombocytopenia that responds adequately to corticosteroid treatment and since then, he had suffered a few controlled relapses. His only medication at the time of the study was Hhex acetaminophen and ibuprofen. No other relevant medical history was found. Looking for an impairment of glucose metabolism due to the hypoglycemic crises, a biochemical blood test was requested to the laboratory. It included the measurement of fasting glucose, glycated hemoglobin (Hb A1c), insulin, C-peptide and some islet autoantibodies: anti-insulin antibodies, antibodies against the 65-kD isoform of Glutamic Acid Decarboxylase (GAD65) and again the Islet Antigen 2 (IA2). The main result of this patient’s examination was the elevated concentration of serum Insulin: 201 U/mL (2.6C24.9), which did not fit to C-peptide value: 2.02 ng/mL (1.1C4.4). The possibilities of insulin injection or abnormal excess of insulin secretion were ruled out. Besides, a high titer of anti-insulin Ticlopidine HCl antibodies was found, suggesting the presence of an autoimmune syndrome as they are common markers of type 1 diabetes mellitus. Serum glucose (74 mg/dL) and Hb A1c (5.3%) result within expected values as the patient did not have diabetes mellitus. The screening for Anti GAD65 and Anti IA2 antibodies was unfavorable, so autoimmune diabetic disorders or other endocrine disorders were ruled out. This discrepancy between the high serum insulin and normal C-peptide levels, in a context of normal fasting blood glucose level, and the presence of IAA, led to the performance.